Inogen, Inc. announced that it will report its third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. The medical technology company will host a conference call to discuss the earnings on the same day.

Earnings call details

The conference call is scheduled for 5:00 pm Eastern Time, which corresponds to 2:00 pm Pacific Time. Individuals interested in listening to the call may dial in using the numbers provided below. A live audio webcast and an archived recording will be available through the News / Events page on the company's Investor Relations website.

Replay availability

A replay of the conference call will be available approximately three hours after the live webcast ends. The replay can be accessed through November 12, 2026. Listeners must dial one of the following numbers and reference Conference ID: 13762851.

• U.S. domestic callers: (877) 660-6853
• Non-U.S. callers: (201) 612-7415

Company profile and disclosure policy

Inogen is a global medical technology company offering innovative respiratory products for use in the homecare setting. The company develops, manufactures, and markets respiratory therapy devices for patients with chronic respiratory conditions. It partners with patients, prescribers, home medical equipment providers, and distributors to make its products widely available.

The company has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Inogen Inc reported second-quarter fiscal year 2026 revenue of $95.1 million, a 3% year-over-year increase, primarily driven by strong international expansion and contributions from new product lines.

The company’s adjusted EBITDA improved by 15% to $2.4 million, reflecting enhanced operational efficiency despite structural shifts in the U.S. sales channel. While international sales surged 15%, U.S. revenues declined 2% as the transition from direct-to-consumer to business-to-business models continued to impact top-line figures.

Financial performance highlights

The quarter showcased a divergence between geographic performance and profitability metrics. International operations remained the primary growth engine, marking the tenth consecutive quarter of double-digit growth in that segment. Conversely, the U.S. market faced headwinds from channel mix dynamics, where traditional rental and direct sales channels contracted while distributor-based B2B sales expanded.

Note: Prior year figures derived from stated percentage changes.

Channel mix and operational trends

Management highlighted that the decline in U.S. sales was largely due to a structural shift in the home respiratory care market. Home Medical Equipment (HME) providers are increasingly prescribing portable oxygen concentrators (POCs) from day one, bypassing the traditional rental funnel. This trend benefits Inogen’s B2B channel but pressures its direct-to-consumer and rental segments.

Key operational observations include:

• International Momentum: Revenue reached $41.3 million, up 15% YoY, with expansion into Eastern Europe and Latin America contributing significantly.
• U.S. Dynamics: Total U.S. unit volume grew high single digits, indicating robust underlying demand despite the $11.6 million rental revenue falling 12% YoY.
• New Products: The Voxi stationary concentrator and Aurora CPAP masks contributed over 100 basis points to total revenue growth, signaling successful market entry for these adjacent categories.

Guidance adjustments

Inogen revised its full-year FY26 outlook, lowering revenue guidance to $355–$361 million from the previous range of $366–$373 million. This reduction reflects anticipated timing delays in international distributor inventory purchases and continued pressure on the U.S. direct business. However, the company raised its full-year adjusted EBITDA guidance to approximately $4 million, representing 48% growth over FY25 levels, citing disciplined cost management and gross margin expansion.

What the numbers show

A notable divergence exists between top-line guidance cuts and bottom-line improvement. While revenue projections were trimmed due to external channel mix shifts and distributor inventory management, adjusted EBITDA guidance was raised. This suggests that management’s focus on cost structure alignment and higher-margin B2B transactions is successfully offsetting volume-driven revenue headwinds. Additionally, the company maintained a debt-free balance sheet with $107 million in cash and equivalents, providing flexibility for ongoing investments in product innovation such as the Simeox airway clearance therapy.